PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1775022
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1775022
Global Monkeypox Vaccine and Treatment Market to Reach US$160.5 Million by 2030
The global market for Monkeypox Vaccine and Treatment estimated at US$100.4 Million in the year 2024, is expected to reach US$160.5 Million by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Monkeypox Vaccines, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$107.2 Million by the end of the analysis period. Growth in the Monkeypox Drugs segment is estimated at 10.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$27.4 Million While China is Forecast to Grow at 12.5% CAGR
The Monkeypox Vaccine and Treatment market in the U.S. is estimated at US$27.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$34.2 Million by the year 2030 trailing a CAGR of 12.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.
The resurgence of monkeypox in multiple regions across the globe has led to a significant rise in demand for effective vaccines and treatments. Previously considered a rare zoonotic disease confined to Central and West Africa, monkeypox has now spread to numerous countries, prompting the World Health Organization (WHO) and public health agencies to classify it as a growing global health threat. The emergence of human-to-human transmission in urban settings has intensified the urgency for immunization campaigns and antiviral treatments to curb outbreaks. Governments and health organizations have increased funding for vaccine procurement and distribution, particularly for high-risk populations such as immunocompromised individuals, healthcare workers, and those exposed to infected individuals. The need for long-term immunity against potential future outbreaks has also accelerated research into next-generation vaccines with improved efficacy and longer-lasting protection.
The development of vaccines and therapeutics for monkeypox has been significantly influenced by advances in virology, immunology, and biotechnology. The most widely used vaccines are modified vaccinia virus Ankara (MVA)-based vaccines, originally developed for smallpox but repurposed due to their cross-protective immunity against monkeypox. Next-generation vaccines with improved safety profiles and higher scalability are under development, aiming to provide long-term immunity with fewer side effects. In parallel, antiviral treatments such as tecovirimat (TPOXX), brincidofovir, and cidofovir have been identified as effective options for reducing symptom severity and preventing complications. The integration of monoclonal antibodies into treatment regimens is also being explored to enhance immune response in severe cases. Additionally, mRNA vaccine technology, which revolutionized COVID-19 vaccination, is being studied for its potential application in developing targeted monkeypox vaccines with rapid adaptability to emerging viral mutations. With increasing investment in research and development, the future of monkeypox vaccines and treatments looks promising, offering improved protection and treatment outcomes.
Governments worldwide have implemented aggressive vaccination strategies and treatment access programs to control the spread of monkeypox, driving market demand for vaccines and therapeutics. Emergency use authorizations (EUAs) and fast-track approvals by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accelerated the availability of vaccines and antiviral drugs. National immunization programs have prioritized at-risk populations, leading to increased vaccine distribution and deployment of stockpiled smallpox vaccines. Public awareness campaigns and community health initiatives have further contributed to vaccination uptake and early treatment adoption. Additionally, funding initiatives by global health organizations, including the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI), have supported large-scale clinical trials and expanded vaccine manufacturing capabilities. As governments continue to prioritize pandemic preparedness, investment in monkeypox vaccine and treatment research is expected to rise.
The growth in the monkeypox vaccine and treatment market is driven by several factors, including the rising number of cases, advancements in vaccine development, and strong government intervention. The increased focus on pandemic preparedness and biosecurity measures has led to higher investments in vaccine research and global stockpiling of antiviral drugs. The expansion of production facilities and improvements in vaccine distribution channels are also fueling market growth. Additionally, the shift toward novel vaccine technologies, including mRNA-based formulations, is creating new opportunities for market expansion. The growing adoption of mass immunization programs and proactive testing strategies is further driving demand for monkeypox-related medical interventions. Furthermore, public-private partnerships between pharmaceutical companies and governments are ensuring rapid vaccine rollout and equitable access to treatments. As monkeypox continues to pose a public health threat, the market for vaccines and treatments is expected to witness sustained growth, driven by ongoing research and global vaccination initiatives.
SCOPE OF STUDY:
The report analyzes the Monkeypox Vaccine and Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product Type (Monkeypox Vaccines, Monkeypox Drugs); Gender (Male Gender, Female Gender, Other Genders); Administration Route (Oral Administration, Injectable Administration); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 32 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.